Author(s):
Priyanka B. Varne, Ashok A. Hajare, Pournima S. Sankpal, Shubham J. Kamble, K. S. Patil
Email(s):
ashok.hajare@bharatividyapeeth.edu
DOI:
10.52711/0974-360X.2025.00882 
Address:
Priyanka B. Varne1, Ashok A. Hajare2*, Pournima S. Sankpal3, Shubham J. Kamble4, K. S. Patil5
1,4Bharati Vidyapeeth College of Pharmacy, Kolhapur, Maharashtra, India 416013.
2,3Bharati Vidyapeeth College of Pharmacy, Palus, Maharashtra, India 416310.
5Tatyasaheb Kore College of Pharmacy, Warnanagar, Maharashtra, India 416113.
*Corresponding Author
Published In:
Volume - 18,
Issue - 12,
Year - 2025
ABSTRACT:
Bosentan is a BCS class II drug having a problem of oral bioavailability. This research work gives an idea of solid lipid nanoparticles (SLN) as a drug carrier system for enhancing solubility of the poorly water soluble drug. According to the results, bosentan solubility is greatly increased by SLN; the optimized batch showed a solubility of roughly 64.37±0.33 µg/mL. An optimized SLN batch was analyzed using DSC, FTIR, XRD, SEM, and TEM. The XRD analysis indicated a transition of the drug's crystalline characteristics to an amorphous state, resulting in a smoother and larger particle surface area compared to its crystalline form, which subsequently enhances solubility. SEM images indicate that the optimized batch contains spherical globules within the nanometric range. The detected particle size in TEM was determined to be precisely 100 nm, which is comparable to the particle size recorded in DLS. TEM pictures showed a smooth-surfaced, spherical shape. After 12 h, the in vitro investigation reveals 94.59% drug release. In accordance with ICH recommendations, the optimized batch was also examined for an accelerated stability assessment in a stability chamber at 25 ºC ±2 ºC and 60±5% relative humidity (RH). The optimized batch (SLN 6) did not exhibit any signs of color or particle size changes.
Cite this article:
Priyanka B. Varne, Ashok A. Hajare, Pournima S. Sankpal, Shubham J. Kamble, K. S. Patil. Bosentan Solid Lipid Nanoparticle Development and Statistical Optimization Using 32 Full Factorial Design. Research Journal Pharmacy and Technology. 2025;18(12):6101-9. doi: 10.52711/0974-360X.2025.00882
Cite(Electronic):
Priyanka B. Varne, Ashok A. Hajare, Pournima S. Sankpal, Shubham J. Kamble, K. S. Patil. Bosentan Solid Lipid Nanoparticle Development and Statistical Optimization Using 32 Full Factorial Design. Research Journal Pharmacy and Technology. 2025;18(12):6101-9. doi: 10.52711/0974-360X.2025.00882 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2025-18-12-72
REFERENCES:
1. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery: a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics 2000;50(1): 161-77.
2. Khurana S., Bedi PMS and Jain NK. Preparation and evaluation of solid lipid nanoparticles based nanogel for dermal delivery of meloxicam. Chemistry and Physics of Lipids. 2013;175–176:65–72.
3. Katouzian I, Faridi EA, Jafari SM and Akhavan S. Formulation and application of a new generation of lipid nano-carriers for the food bioactive ingredients. Trends in Food Science and Technology. 2017; 68: 14–25.
4. Aljurbui SJ, Hussain A, Yusuf M, et al. Impact of composition and morphology of ketoconazole-loaded solid lipid nanoparticles on intestinal permeation and gastroplus-based prediction studies. American Chemical Society Omega. 2022;7(26):22406–20.
5. Benza RL, Miller DP, Barst RJ et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal registry. Chest. 2012;142(2):448–56.
6. Humbert M, Sitbon O and Simonneau G. Treatment of pulmonary arterial hypertension. The New England Journal of Medicine. 2004;351(14): 1425-36.
7. Saigal A, Ng WK, Tan RBH and Chan SY. Development of controlled release inhalable polymeric microspheres for treatment of pulmonary hypertension. International Journal of Pharmaceutics. 201;450(1–2):114–22.
8. Williamson DJ, Wallman LL, Jones R, et al. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation. 2000;102(4):411-8.
9. O’Callaghan DS. Emerging treatments for pulmonary arterial hypertension, The Clinical Respiratory Journal. 2008;2(3):132–140.
10. Nahar K, Absar S, Patel B and Ahsan F. Starch-coated magnetic liposomes as an inhalable carrier for accumulation of fasudil in the pulmonary vasculature. International Journal of Pharmaceutics. 2014;464(1–2):185–95.
11. Gabbay E, Fraser J and Mcneil K. Review of bosentan in the management of pulmonary arterial hypertension. Vascular Health and Risk Management. 2007;3(6): 887-900.
12. Valerio CJ and Coghlan JG. Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. Vascular Health and Risk Management. 2009; 5:607-19.
13. Hanna LA, Basalious EB and ElGazayerly ON. Respirable controlled release polymeric colloid (RCRPC) of bosentan for the management of pulmonary hypertension: In vitro aerosolization, histological examination and in vivo pulmonary absorption. Drug Delivery. 2012;24(1):188–98.
14. Kumar L and Verma R. Determination of saturated solubility of propranolol using UV visible spectrophotometer. Scholars Research Library Der Pharmacia Lettre. 2016;8(17):196–201.
15. Bhalekar M, Upadhaya P and Madgulkar A. Formulation and characterization of solid lipid nanoparticles for an anti-retroviral drug darunavir. Applied Nanoscience. 2017;7(1–2):47–57.
16. Arora R, Katiyar SS, Kushwah V and Jain S. Solid lipid nanoparticles and nanostructured lipid carrier-based nanotherapeutics in treatment of psoriasis: a comparative study. Expert Opinion Drug Delivery. 2017;14(2):165–77.
17. Boonme P, Souto EB, Wuttisantikul N, et al. Influence of lipids on properties of solid lipid nanoparticles from microemulsion technique. European Journal of Lipid Science and Technology. 2013;115(7):820-824.
18. Kakkar V, Singh S, Singla D and Kaur IP. Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Molecular Nutrition and Food Research 2011;55(3):495–503.
19. Helgason T, Salminen H, Kristbergsson K, et al. Formation of transparent solid lipid nanoparticles by microfluidization: Influence of lipid physical state on appearance. Journal of Colloid and Interface Science. 2015; 448:114 – 22.
20. Singh S, Dobhal AK, Jain A, Pandit K and Chakraborty S. Formulation and evaluation of solid lipid nanoparticles of a water soluble drug: zidovudine. Chemical Pharmaceutical Bulletin. 2010; 58(5): 650-5.
21. El-Emam GA, Girgis GN, Hamed MF, et al. Formulation and pathohistological study of mizolastine–solid lipid nanoparticles–loaded ocular hydrogels. International Journal of Nanomedicine. 2021; 16:7775–99.
22. Patil KS., Hajare AA, Manjappa AS. Design, development, in silico and in vitro characterization of Docetaxel-loaded TPGS/ Pluronic F 108 mixed micelles for improved cancer treatment. Journal of Drug Delivery Science and Technology. 2021 Oct 1;65.
23. Hajare AA, Velapure PD, Patil KS. Formulation and evaluation of solid lipid nanoparticle gel for topical delivery of clobetasol propionate to enhance its permeation using silk sericin as permeation enhancer. International Journal of Pharmaceutical Sciences and Research. 2020;11(5);2356-2365.
24. Yadav PS., Hajare AA, and Patil KS. Development of doxazosin mesylate liquisolid system for improved manufacturing processability and bioavailability: in vitro and in vivo evaluation for tailored hypertension treatment approach with modified dissolution rates. Journal of Dispersion Science and Technology. 2024; 45(6):1227-40.
25. Yadav PS, Hajare AA, Patil KS. Design and development of Fujicalin-based axitinib liquisolid compacts for improved dissolution and bioavailability to treat renal cell carcinoma. European Journal of Pharmaceutics and Biopharmaceutics. 2024; 204:114506.
26. Yadav PS, Hajare AA, Patil KS. Development and validation of UV spectrophotometric method for doxazosin mesylate in bulk and tablets. Research Journal of Pharmacy and Technology. 2022; 15(6):2675-80.
27. Yadav PS, Kondawar MS., Varne BS. Enhancement of dissolution properties of candesartan using liquisolid technique. International Journal of Advances in Pharmaceutical Research. 2013;4(2):2503-13.